Home » Stocks » CTDH

Cyclo Therapeutics Inc. (CTDH)

Dec 9, 2020 - Stock symbol was changed to CYTH
Stock Price: $4.19 USD -0.01 (-0.24%)
Updated Dec 11, 2021 9:30 AM EST
Market Cap 14.62M
Revenue (ttm) 985,153
Net Income (ttm) -8.90M
Shares Out 151.95M
EPS (ttm) -0.06
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day Dec 11, 2021
Last Price $4.19
Previous Close $4.20
Change ($) -0.01
Change (%) -0.24%
Day's Open 4.17
Day's Range 4.00 - 4.24
Day's Volume 93,402
52-Week Range 3.55 - 34.99

News

There are no news available yet.

About CTDH

Cyclo Therapeutics, a biotechnology company, develops cyclodextrin-based products for the treatment of diseases. Its lead drug candidate is Trappsol Cyclo, an orphan drug for the treatment of Niemann-Pick Type C disease. The company also sells cyclodextrins and related products to the pharmaceutical, nutritional, and other industries, primarily for use in diagnostics and specialty drugs. It has a collaboration with the Chattanooga Center for Neurologic Research. The company was formerly known as CTD Holdings, Inc. and changed its name to Cyclo ... [Read more...]

Industry
Biotechnology
Founded
1990
CEO
N. Scott Fine
Employees
5
Stock Exchange
OTCMKTS
Ticker Symbol
CTDH
Full Company Profile

Financial Performance

In 2019, CTDH's revenue was $1.01 million, a decrease of -0.42% compared to the previous year's $1.01 million. Losses were -$7.53 million, 77.0% more than in 2018.

Financial Statements